Fresenius Medical Care says MOTheR trial does not show mortality non-inferiority for medium cut-off dialyzers vs OL-HDF

• FMC defended high-volume hemodiafiltration as the only advanced dialysis modality with large multinational randomized evidence of lower all-cause mortality.
• It said the MOTheR non-inferiority study of medium cut-off dialyzers versus online HDF should not be read as showing comparable mortality outcomes.
• The response cited wide confidence intervals, a 25% non-inferiority margin, multiple unplanned interim analyses, single-country design, less than 30% complete follow-up.
• FMC pointed to the CONVINCE trial in the New England Journal of Medicine, which reported a 23% all-cause mortality reduction with high-volume hemodiafiltration.
• It said treatment choices should reflect the full evidence base, including multinational trials, real-world experience, consistent delivery, and monitoring of convective dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FMC - Fresenius Medical Care AG published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.